A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Brief description of study
The main goal of this phase III study is to evaluate whether adjuvant therapy with crizotinib (an ATP blocker of several tyrosine kinases) will result in improved overall survival compared to placebo in people with Anaplastic Lymphoma Kinase-positive non-small cell lung cancer. Also, we will evaluate how well crizotinib is tolerated in your body.
Clinical Study Identifier: s16-02072
ClinicalTrials.gov Identifier: NCT02201992
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
